Molecular Diagnosis in Hymenoptera Allergy: Comparison of Euroline DPA-Dx and ImmunoCAP.

IF 3.9 3区医学 Q2 FOOD SCIENCE & TECHNOLOGY

Toxins Pub Date : 2025-06-19 DOI:10.3390/toxins17060310

Lluís Marquès, Arantza Vega, Federico de la Roca, Carmen Domínguez, Víctor Soriano-Gomis, Teresa Alfaya, Laia Ferré-Ybarz, José-María Vega, Mario Tubella, Berta Ruiz-León

{"title":"Molecular Diagnosis in Hymenoptera Allergy: Comparison of Euroline DPA-Dx and ImmunoCAP.","authors":"Lluís Marquès, Arantza Vega, Federico de la Roca, Carmen Domínguez, Víctor Soriano-Gomis, Teresa Alfaya, Laia Ferré-Ybarz, José-María Vega, Mario Tubella, Berta Ruiz-León","doi":"10.3390/toxins17060310","DOIUrl":null,"url":null,"abstract":"The efficacy of Hymenoptera venom immunotherapy is contingent upon the accurate identification of the insect responsible for the allergic reaction. The techniques used to detect specific IgE suffer from difficulties due to the cross-reactivity between Hymenoptera venoms (false positives), diagnostic ability, and the limited availability of allergenic components (false negatives). In this study, we analyzed the discrepancies in the results obtained with Euroline® DPA-Dx and ImmunoCAP® in the diagnosis of allergic reactions due to Hymenoptera stings in 151 patients. The results (positive/negative) of ImmunoCAP® and Euroline® agreed in 77/151 (50.99%) cases; with 15/151 (9.93%) cases positive for the same insect, and 61/151 (40.4%) cases positive for multiple insects. When the results were used to decide which venom to use for immunotherapy, there was a statistically significant discrepancy for Polistes dominula (21.8% of cases with ImmunoCAP® compared to only 8.4% with Euroline®). The presence of Polistes venom phospholipase (Pol d 1) in Euroline® did not increase its ability to differentiate double sensitization to wasps. ImmunoCAP® and Euroline® exhibited comparable diagnostic performance in bee venom allergy. For vespid venom allergy-particularly involving Polistes species-ImmunoCAP® appeared to show a slight diagnostic advantage, although this finding should be interpreted with caution.","PeriodicalId":23119,"journal":{"name":"Toxins","volume":"17 6","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12197634/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Toxins","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/toxins17060310","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"FOOD SCIENCE & TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The efficacy of Hymenoptera venom immunotherapy is contingent upon the accurate identification of the insect responsible for the allergic reaction. The techniques used to detect specific IgE suffer from difficulties due to the cross-reactivity between Hymenoptera venoms (false positives), diagnostic ability, and the limited availability of allergenic components (false negatives). In this study, we analyzed the discrepancies in the results obtained with Euroline^® DPA-Dx and ImmunoCAP^® in the diagnosis of allergic reactions due to Hymenoptera stings in 151 patients. The results (positive/negative) of ImmunoCAP^® and Euroline^® agreed in 77/151 (50.99%) cases; with 15/151 (9.93%) cases positive for the same insect, and 61/151 (40.4%) cases positive for multiple insects. When the results were used to decide which venom to use for immunotherapy, there was a statistically significant discrepancy for Polistes dominula (21.8% of cases with ImmunoCAP^® compared to only 8.4% with Euroline^®). The presence of Polistes venom phospholipase (Pol d 1) in Euroline^® did not increase its ability to differentiate double sensitization to wasps. ImmunoCAP^® and Euroline^® exhibited comparable diagnostic performance in bee venom allergy. For vespid venom allergy-particularly involving Polistes species-ImmunoCAP^® appeared to show a slight diagnostic advantage, although this finding should be interpreted with caution.

查看原文本刊更多论文

膜翅目变态反应的分子诊断：Euroline DPA-Dx和ImmunoCAP的比较。

膜翅目毒液免疫疗法的疗效取决于对引起过敏反应的昆虫的准确识别。由于膜翅目毒液之间的交叉反应性（假阳性）、诊断能力和致敏成分的有限可用性（假阴性），用于检测特定IgE的技术存在困难。在这项研究中，我们分析了Euroline®DPA-Dx和ImmunoCAP®在诊断151例膜翅目昆虫蜇伤引起的过敏反应中的差异。免疫cap®和Euroline®的阳性/阴性结果在77/151（50.99%）病例中一致；同一昆虫阳性15/151例（9.93%），多种昆虫阳性61/151例（40.4%）。当结果被用来决定使用哪种毒液进行免疫治疗时，在统计上有显著差异的是Polistes dominula（21.8%的病例使用ImmunoCAP®，而只有8.4%的病例使用Euroline®）。在Euroline®中存在Polistes毒液磷脂酶（pold 1）并没有增加其对黄蜂的双重致敏能力。ImmunoCAP®和Euroline®在蜂毒过敏诊断中的表现相当。对于蛇毒过敏，特别是涉及Polistes物种，immunocap®似乎显示出轻微的诊断优势，尽管这一发现应谨慎解释。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Toxins TOXICOLOGY-

CiteScore

7.50

自引率

16.70%

发文量

765

审稿时长

16.24 days

期刊介绍： Toxins (ISSN 2072-6651) is an international, peer-reviewed open access journal which provides an advanced forum for studies related to toxins and toxinology. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.